How to produce video for healthcare and pharma

Why healthcare and pharma video carries a different production load

Healthcare and pharma video sits under the heaviest regulatory load of any enterprise sector. FDA in the US, EMA in Europe, MHRA in the UK, PMDA in Japan, TGA in Australia all have specific rules for promotional content carrying a medical claim. Industry codes (PhRMA, EFPIA, ABPI, Medicines Australia) sit on top of regulator rules. The result: medical-legal-regulatory (MLR) review at multiple stages, fair-balance and risk-disclosure language baked into every claim, audit trails retained against the possibility of regulator inspection.

Most enterprise programs underestimate the structural impact. They start out treating healthcare video like any other corporate video, then run into the MLR chain on every asset and end up shipping a fraction of the planned volume because review cycles compound. The structural shift: design the production workflow around MLR from day one. Tag every asset by audience at brief stage. Route to the right MLR depth. Capture the audit trail at every gate. This post is a guide to building (or evaluating) a video program that handles the healthcare and pharma specifics properly.

The four content surfaces

Surface 1: Patient-facing (DTC)

Direct-to-consumer disease-awareness video, treatment explainers, adherence-support content, patient-journey stories. Highest MLR scrutiny because the audience is non-expert and the regulator standard is highest. Fair-balance disclosures, indication match, risk language all required. Voiceover and on-screen text must align exactly with approved labelling. Cost: $15K to $35K per finished piece. Volume: 8 to 16 finished pieces per year for most enterprise pharma DTC programs.

Surface 2: HCP-facing (healthcare professional)

Mechanism of action explainers, clinical-data summaries, sales rep enablement, congress booth video, MSL (medical science liaison) training. Standard MLR tier because the audience is regulated to expect promotional context and is presumed clinically literate. Volume: 20 to 40 finished pieces per year typical. Cost: $8K to $20K per piece. Often the largest content surface because the field force and HCP marketing both pull from this catalogue.

Surface 3: Internal training

Field force onboarding, launch readiness training, recertification modules, internal product-update communications. Lighter compliance review (internal audiences are presumed to know the regulatory context). Volume: 30 to 80 pieces per year typical. Cost: $3K to $8K per piece. Cycle time is the shortest of the four surfaces (2 to 4 weeks) which is why most pharma programs find the highest production leverage here.

Surface 4: Congress and KOL

Conference recaps, KOL (key opinion leader) interviews, symposium recordings, congress-booth video. HCP-tier compliance review. Volume: 12 to 24 pieces per year tied to congress calendar. Cost: $6K to $15K per piece. Often produced under tight congress timelines which makes pre-built templates and pre-approved KOL contracts the leverage points.

Get a Free Consultation

The MLR review chain

Three sequential reviews plus a final sign-off, with an audit log captured against every gate.

Gate 1: Medical review

Clinical accuracy of every claim. Indication match to the approved label. Evidence cited correctly. References checked against the source studies. This is the deepest review and the one most likely to require script edits before production starts. Most pharma programs we work with run script-gate medical review on a 5 to 10 day SLA for routine content and longer for new claims.

Gate 2: Legal review

Fair-balance language (every benefit claim paired with appropriate risk language). Off-label risk (any language that could imply off-label use removed). IP and trademark clearance. Industry-code compliance (PhRMA in US, EFPIA in EU, ABPI in UK, Medicines Australia code). Reviews on the script and again on the final cut.

Gate 3: Regulatory review

Specific to the asset and jurisdiction. Some assets require regulator submission before publication; most require regulator-ready archival for inspection on request. The regulatory reviewer checks that the asset matches what would be submittable to FDA, EMA, MHRA, PMDA or TGA depending on jurisdiction.

Final MLR sign-off and audit trail

All three reviewers sign off the final cut. Audit log captures who approved what, when, on which version, with which evidence references. Retained 7 years (FDA standard) or longer per local requirement. The audit log is the asset that protects the company from regulator action, because most enforcement is triggered by a single missed gate that the audit log can either defend against or expose.

The cycle-time pattern that holds

Healthcare video cycle time is roughly 2 to 3x equivalent unregulated video, driven by the MLR chain. The pattern that works:

Pattern 1: Front-load the review

Script-gate review at the brief stage catches structural issues (off-label risk, missing disclosures, language that triggers specific regulator categories) at the cheapest stage to fix them. Most production teams that struggle with cycle time are running MLR review too late in the cycle.

Pattern 2: Parallel-track production and review

Production proceeds in parallel with legal and regulatory review of the script. Edit begins in parallel with medical review of the first cut. Most cycle-time wins come from removing sequential dependencies that do not need to be sequential.

Pattern 3: Pre-approved templates

Brand and disclosure templates pre-approved by MLR for the specific content category. Editors and producers work inside the template; reviewers focus on the variable content. Most enterprise pharma programs that ship at high volume have invested heavily in MLR-approved templates because the per-asset review overhead drops 30 to 50 percent.

Pattern 4: Modular MLR review

Reusable copy blocks (indication, ISI, references, contact info) approved once and reusable across assets. Saves the reviewer the load of re-checking the same content in every asset. Saves the editor the load of waiting for repeated review.

Multi-jurisdiction sign-off for global pharma

Regulators vary substantially by jurisdiction; production patterns stay consistent.

US: FDA and FTC oversight

FDA regulates prescription drug promotion through OPDP (Office of Prescription Drug Promotion). DTC video specifically requires fair-balance treatment, major statement, adequate provision. FTC oversees OTC and supplement video. State-level requirements layer on top in California (Prop 65), New York and a handful of other states.

EU and UK: EMA, MHRA and industry codes

EMA sets EU-wide rules for prescription medicine promotion. National competent authorities (BfArM Germany, ANSM France, AIFA Italy, AEMPS Spain) handle local enforcement. UK MHRA operates post-Brexit independently with ABPI code for industry self-regulation. EFPIA code applies across the EU.

APAC: PMDA, TGA, HSA and others

Japan PMDA, Australia TGA, Singapore HSA, Korea MFDS each have specific rules. APAC pharma video frequently requires per-market versioning because regulator differences are substantial. Most global pharma firms produce master content with regional adaptation rather than separate per-market originals.

The workflow that scales

One source content, regional MLR review chains, per-jurisdiction final sign-off. Same production team, same brand templates, multiple compliance review chains. This holds production cost consistent while respecting regulator differences. We covered the broader multi-jurisdiction sign-off pattern in how to produce video for financial services; the structural pattern is similar but the review chain is deeper for healthcare.

Patient confidentiality and HIPAA

Any video involving identifiable patients requires HIPAA (US) or equivalent (GDPR in EU, Privacy Act in Australia) consent documentation. Patient testimonials carry additional consent burden because the audience uses them to evaluate treatment decisions. Standard pharma practice: documented consent at recording, additional consent for distribution channel, retention of consent records for the lifetime of the content plus a regulator-set window after withdrawal.

Most pharma video programs maintain a consent template library covering recording consent, distribution consent, channel-specific consent (social media has stricter requirements than gated medical channels). Production workflow tags every patient-identifiable asset and routes through the consent-verification gate before publication.

What changes for the production team working on healthcare content

Three practical shifts the production team has to make.

Shift 1: Sector literacy

Producers and editors who understand the difference between a Phase II and Phase III study, what fair-balance disclosure looks like, what risk language tone is regulator-acceptable, why indication match matters. This is not creative judgment; it is sector literacy that reduces the back-and-forth at MLR review. Most enterprise pharma programs train their production team specifically on these patterns.

Shift 2: Template-led editing

Disclaimer placement, ISI (important safety information) timing, reference citation, contact info all sit in pre-approved brand templates with the right typography, duration and placement per jurisdiction. The editor knows where every regulator-required element goes in the timeline rather than waiting for MLR to ask for it.

Shift 3: Secure handling of clinical data

Clinical study data, unpublished trial results, patient-identifiable material handled per the company's data classification policy. Production happens in restricted-access workspaces with controlled access lists. Mirrors the IR video controls we covered in how to produce video for investor relations but with extra patient-data protections layered on top.

How AI fits inside healthcare video production

Useful in narrow places, prohibited in others. Transcript extraction, voice-over generation in non-regulated languages, social clip selection, distribution scheduling all benefit from AI inside the production workflow. Direct AI generation of medical content (claims, indications, risk language) is prohibited at most enterprise pharma firms because the trust signal in healthcare content is the clinical sign-off. The framing in how AI fits inside enterprise video workflows applies with extra caution for healthcare.

Practical questions enterprise healthcare and pharma teams ask

How long does MLR review actually take?

Routine content: 2 to 4 weeks total across the three gates plus final sign-off. Complex content (new indication, new claim, head-to-head comparison): 6 to 12 weeks. Total wall-clock impact is roughly 2 to 3x equivalent unregulated content. Rush-tier content can compress these windows with pre-agreed expedited review but MLR teams resist routine expedition.

Can we use generative AI to draft clinical scripts?

Most enterprise pharma firms prohibit AI-generated medical content at the script stage. AI is useful for transcript editing, social cutdown selection and distribution scheduling but not as a primary production method for regulated medical content. The trust signal in healthcare is the human clinical sign-off chain.

How do we handle multi-market localisation?

Master content produced once, per-market adaptations (regional disclosures, language localisation, regulator-required additions) derived from the master and reviewed by each jurisdiction's MLR team separately. The audit trail captures each jurisdiction's approval independently.

What about social-first healthcare content?

The newest area of regulator attention. FTC enforcement against unregistered health promotion on social, FDA OPDP guidance on social pharma promotion, TGA Australia social-influencer guidance. Production workflow should anticipate frequent guidance updates and build in faster review cycles for social-first content than traditional channels.

How do we handle patient testimonials?

Highest-risk content category. Most pharma firms route patient testimonial video through extra-stringent MLR review with specific consent documentation, atypical-result disclaimers and clear distinction between editorial content and promotional content. Consent records retained for the lifetime of the content.

Where to go next

For the financial services equivalent of the regulator-aware workflow, read how to produce video for financial services. For the IR video workflow that overlaps with healthcare for public-company pharma firms, read how to produce video for investor relations. For the contract patterns that govern data security and audit trails, read video production contracts: what to look for.

To scope a healthcare or pharma video program with MLR-ready workflow for your organization, book a free consultation.